nodes	percent_of_prediction	percent_of_DWPC	metapath
Modafinil—CYP3A4—bone cancer	0.712	1	CbGaD
Modafinil—CYP2B6—Cisplatin—bone cancer	0.0282	0.416	CbGbCtD
Modafinil—CYP2B6—Doxorubicin—bone cancer	0.0189	0.279	CbGbCtD
Modafinil—CYP2C9—Cisplatin—bone cancer	0.0149	0.22	CbGbCtD
Modafinil—CYP3A4—Doxorubicin—bone cancer	0.00581	0.0856	CbGbCtD
Modafinil—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00237	0.0635	CbGpPWpGaD
Modafinil—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00132	0.0354	CbGpPWpGaD
Modafinil—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00129	0.0346	CbGpPWpGaD
Modafinil—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00111	0.0298	CbGpPWpGaD
Modafinil—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.001	0.0268	CbGpPWpGaD
Modafinil—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000911	0.0244	CbGpPWpGaD
Modafinil—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000871	0.0233	CbGpPWpGaD
Modafinil—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000871	0.0233	CbGpPWpGaD
Modafinil—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00083	0.0222	CbGpPWpGaD
Modafinil—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000779	0.0209	CbGpPWpGaD
Modafinil—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000715	0.0191	CbGpPWpGaD
Modafinil—Nepafenac—PTGS2—bone cancer	0.000694	0.0894	CrCbGaD
Modafinil—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00065	0.0174	CbGpPWpGaD
Modafinil—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000638	0.0171	CbGpPWpGaD
Modafinil—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000624	0.0167	CbGpPWpGaD
Modafinil—Fosphenytoin—CYP3A4—bone cancer	0.000613	0.0789	CrCbGaD
Modafinil—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000601	0.0161	CbGpPWpGaD
Modafinil—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.0006	0.0161	CbGpPWpGaD
Modafinil—Oxaprozin—PTGS2—bone cancer	0.000577	0.0743	CrCbGaD
Modafinil—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000569	0.0152	CbGpPWpGaD
Modafinil—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000565	0.0151	CbGpPWpGaD
Modafinil—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000556	0.0149	CbGpPWpGaD
Modafinil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000492	0.0132	CbGpPWpGaD
Modafinil—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000482	0.0129	CbGpPWpGaD
Modafinil—Fenoprofen—PTGS2—bone cancer	0.000477	0.0614	CrCbGaD
Modafinil—Bifonazole—CYP3A4—bone cancer	0.000464	0.0598	CrCbGaD
Modafinil—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000464	0.0124	CbGpPWpGaD
Modafinil—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000449	0.012	CbGpPWpGaD
Modafinil—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00044	0.0118	CbGpPWpGaD
Modafinil—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000438	0.0117	CbGpPWpGaD
Modafinil—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00043	0.0115	CbGpPWpGaD
Modafinil—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000428	0.0115	CbGpPWpGaD
Modafinil—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000423	0.0113	CbGpPWpGaD
Modafinil—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000421	0.0113	CbGpPWpGaD
Modafinil—Phenprocoumon—CYP3A4—bone cancer	0.00042	0.0541	CrCbGaD
Modafinil—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000418	0.0112	CbGpPWpGaD
Modafinil—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000409	0.011	CbGpPWpGaD
Modafinil—Oxcarbazepine—CYP3A4—bone cancer	0.000409	0.0526	CrCbGaD
Modafinil—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000392	0.0105	CbGpPWpGaD
Modafinil—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000392	0.0105	CbGpPWpGaD
Modafinil—Phenylbutazone—CYP3A4—bone cancer	0.00039	0.0502	CrCbGaD
Modafinil—Phenylbutazone—PTGS2—bone cancer	0.000381	0.0491	CrCbGaD
Modafinil—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000376	0.0101	CbGpPWpGaD
Modafinil—Warfarin—CYP3A4—bone cancer	0.000373	0.048	CrCbGaD
Modafinil—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000361	0.00968	CbGpPWpGaD
Modafinil—ADRA1B—LPA receptor mediated events—GNA11—bone cancer	0.000359	0.00961	CbGpPWpGaD
Modafinil—Levomethadyl Acetate—CYP3A4—bone cancer	0.000349	0.045	CrCbGaD
Modafinil—Bronchitis—Doxorubicin—bone cancer	0.000337	0.00193	CcSEcCtD
Modafinil—Agranulocytosis—Methotrexate—bone cancer	0.000336	0.00192	CcSEcCtD
Modafinil—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000335	0.00898	CbGpPWpGaD
Modafinil—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000334	0.00191	CcSEcCtD
Modafinil—Pancytopenia—Doxorubicin—bone cancer	0.000332	0.0019	CcSEcCtD
Modafinil—Body temperature increased—Cisplatin—bone cancer	0.000331	0.00189	CcSEcCtD
Modafinil—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000331	0.00887	CbGpPWpGaD
Modafinil—Stomatitis—Epirubicin—bone cancer	0.000329	0.00188	CcSEcCtD
Modafinil—Urinary tract infection—Epirubicin—bone cancer	0.000328	0.00188	CcSEcCtD
Modafinil—Conjunctivitis—Epirubicin—bone cancer	0.000328	0.00188	CcSEcCtD
Modafinil—ADRA1B—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000327	0.00875	CbGpPWpGaD
Modafinil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000325	0.0087	CbGpPWpGaD
Modafinil—Sweating—Epirubicin—bone cancer	0.000323	0.00185	CcSEcCtD
Modafinil—Pollakiuria—Doxorubicin—bone cancer	0.000323	0.00185	CcSEcCtD
Modafinil—Haematuria—Epirubicin—bone cancer	0.000322	0.00184	CcSEcCtD
Modafinil—Pharyngitis—Methotrexate—bone cancer	0.000321	0.00184	CcSEcCtD
Modafinil—Urinary tract disorder—Methotrexate—bone cancer	0.00032	0.00183	CcSEcCtD
Modafinil—Photosensitivity reaction—Doxorubicin—bone cancer	0.00032	0.00183	CcSEcCtD
Modafinil—Weight increased—Doxorubicin—bone cancer	0.000319	0.00182	CcSEcCtD
Modafinil—Epistaxis—Epirubicin—bone cancer	0.000318	0.00182	CcSEcCtD
Modafinil—Urethral disorder—Methotrexate—bone cancer	0.000317	0.00181	CcSEcCtD
Modafinil—Weight decreased—Doxorubicin—bone cancer	0.000317	0.00181	CcSEcCtD
Modafinil—Sinusitis—Epirubicin—bone cancer	0.000317	0.00181	CcSEcCtD
Modafinil—Hyperglycaemia—Doxorubicin—bone cancer	0.000316	0.00181	CcSEcCtD
Modafinil—Agranulocytosis—Epirubicin—bone cancer	0.000315	0.0018	CcSEcCtD
Modafinil—Pneumonia—Doxorubicin—bone cancer	0.000314	0.0018	CcSEcCtD
Modafinil—Drowsiness—Doxorubicin—bone cancer	0.000312	0.00179	CcSEcCtD
Modafinil—Visual impairment—Methotrexate—bone cancer	0.000312	0.00178	CcSEcCtD
Modafinil—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000309	0.00177	CcSEcCtD
Modafinil—Hypersensitivity—Cisplatin—bone cancer	0.000309	0.00177	CcSEcCtD
Modafinil—Bradycardia—Epirubicin—bone cancer	0.000308	0.00176	CcSEcCtD
Modafinil—Erythema multiforme—Methotrexate—bone cancer	0.000306	0.00175	CcSEcCtD
Modafinil—Stomatitis—Doxorubicin—bone cancer	0.000304	0.00174	CcSEcCtD
Modafinil—Rhinitis—Epirubicin—bone cancer	0.000304	0.00174	CcSEcCtD
Modafinil—Urinary tract infection—Doxorubicin—bone cancer	0.000303	0.00174	CcSEcCtD
Modafinil—Conjunctivitis—Doxorubicin—bone cancer	0.000303	0.00174	CcSEcCtD
Modafinil—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000302	0.00809	CbGpPWpGaD
Modafinil—Dextropropoxyphene—CYP3A4—bone cancer	0.000302	0.0389	CrCbGaD
Modafinil—Asthenia—Cisplatin—bone cancer	0.000301	0.00172	CcSEcCtD
Modafinil—Pharyngitis—Epirubicin—bone cancer	0.000301	0.00172	CcSEcCtD
Modafinil—Cardiac disorder—Methotrexate—bone cancer	0.0003	0.00172	CcSEcCtD
Modafinil—Sweating—Doxorubicin—bone cancer	0.000299	0.00171	CcSEcCtD
Modafinil—Urinary tract disorder—Epirubicin—bone cancer	0.000299	0.00171	CcSEcCtD
Modafinil—Fentanyl—CYP3A4—bone cancer	0.000298	0.0384	CrCbGaD
Modafinil—Oedema peripheral—Epirubicin—bone cancer	0.000298	0.00171	CcSEcCtD
Modafinil—Haematuria—Doxorubicin—bone cancer	0.000298	0.0017	CcSEcCtD
Modafinil—Connective tissue disorder—Epirubicin—bone cancer	0.000298	0.0017	CcSEcCtD
Modafinil—Urethral disorder—Epirubicin—bone cancer	0.000297	0.0017	CcSEcCtD
Modafinil—Epistaxis—Doxorubicin—bone cancer	0.000294	0.00168	CcSEcCtD
Modafinil—Angiopathy—Methotrexate—bone cancer	0.000294	0.00168	CcSEcCtD
Modafinil—Sinusitis—Doxorubicin—bone cancer	0.000293	0.00167	CcSEcCtD
Modafinil—Immune system disorder—Methotrexate—bone cancer	0.000292	0.00167	CcSEcCtD
Modafinil—Visual impairment—Epirubicin—bone cancer	0.000292	0.00167	CcSEcCtD
Modafinil—Mediastinal disorder—Methotrexate—bone cancer	0.000292	0.00167	CcSEcCtD
Modafinil—Agranulocytosis—Doxorubicin—bone cancer	0.000291	0.00167	CcSEcCtD
Modafinil—Chills—Methotrexate—bone cancer	0.00029	0.00166	CcSEcCtD
Modafinil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000288	0.00771	CbGpPWpGaD
Modafinil—Diarrhoea—Cisplatin—bone cancer	0.000287	0.00164	CcSEcCtD
Modafinil—Erythema multiforme—Epirubicin—bone cancer	0.000286	0.00164	CcSEcCtD
Modafinil—Bradycardia—Doxorubicin—bone cancer	0.000285	0.00163	CcSEcCtD
Modafinil—Mental disorder—Methotrexate—bone cancer	0.000284	0.00162	CcSEcCtD
Modafinil—Malnutrition—Methotrexate—bone cancer	0.000282	0.00161	CcSEcCtD
Modafinil—Ketoprofen—PTGS2—bone cancer	0.000281	0.0363	CrCbGaD
Modafinil—Cardiac disorder—Epirubicin—bone cancer	0.000281	0.00161	CcSEcCtD
Modafinil—Rhinitis—Doxorubicin—bone cancer	0.000281	0.00161	CcSEcCtD
Modafinil—Carbamazepine—CYP3A4—bone cancer	0.000278	0.0359	CrCbGaD
Modafinil—Pharyngitis—Doxorubicin—bone cancer	0.000278	0.00159	CcSEcCtD
Modafinil—Urinary tract disorder—Doxorubicin—bone cancer	0.000277	0.00158	CcSEcCtD
Modafinil—Oedema peripheral—Doxorubicin—bone cancer	0.000276	0.00158	CcSEcCtD
Modafinil—Dysgeusia—Methotrexate—bone cancer	0.000276	0.00158	CcSEcCtD
Modafinil—Connective tissue disorder—Doxorubicin—bone cancer	0.000275	0.00157	CcSEcCtD
Modafinil—Angiopathy—Epirubicin—bone cancer	0.000275	0.00157	CcSEcCtD
Modafinil—Urethral disorder—Doxorubicin—bone cancer	0.000275	0.00157	CcSEcCtD
Modafinil—Immune system disorder—Epirubicin—bone cancer	0.000274	0.00156	CcSEcCtD
Modafinil—Mediastinal disorder—Epirubicin—bone cancer	0.000273	0.00156	CcSEcCtD
Modafinil—Back pain—Methotrexate—bone cancer	0.000273	0.00156	CcSEcCtD
Modafinil—Chills—Epirubicin—bone cancer	0.000272	0.00155	CcSEcCtD
Modafinil—Phenytoin—CYP3A4—bone cancer	0.000271	0.0349	CrCbGaD
Modafinil—Arrhythmia—Epirubicin—bone cancer	0.000271	0.00155	CcSEcCtD
Modafinil—Visual impairment—Doxorubicin—bone cancer	0.00027	0.00154	CcSEcCtD
Modafinil—Vomiting—Cisplatin—bone cancer	0.000266	0.00152	CcSEcCtD
Modafinil—Mental disorder—Epirubicin—bone cancer	0.000265	0.00152	CcSEcCtD
Modafinil—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000265	0.0071	CbGpPWpGaD
Modafinil—Erythema multiforme—Doxorubicin—bone cancer	0.000265	0.00152	CcSEcCtD
Modafinil—Benzphetamine—CYP3A4—bone cancer	0.000265	0.0341	CrCbGaD
Modafinil—Rash—Cisplatin—bone cancer	0.000264	0.00151	CcSEcCtD
Modafinil—Dermatitis—Cisplatin—bone cancer	0.000264	0.00151	CcSEcCtD
Modafinil—Malnutrition—Epirubicin—bone cancer	0.000264	0.00151	CcSEcCtD
Modafinil—Atomoxetine—CYP3A4—bone cancer	0.000262	0.0338	CrCbGaD
Modafinil—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000262	0.00701	CbGpPWpGaD
Modafinil—Ill-defined disorder—Methotrexate—bone cancer	0.000261	0.00149	CcSEcCtD
Modafinil—Anaemia—Methotrexate—bone cancer	0.00026	0.00149	CcSEcCtD
Modafinil—Cardiac disorder—Doxorubicin—bone cancer	0.00026	0.00149	CcSEcCtD
Modafinil—Flatulence—Epirubicin—bone cancer	0.00026	0.00149	CcSEcCtD
Modafinil—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000259	0.00694	CbGpPWpGaD
Modafinil—Tension—Epirubicin—bone cancer	0.000259	0.00148	CcSEcCtD
Modafinil—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000259	0.00693	CbGpPWpGaD
Modafinil—Dysgeusia—Epirubicin—bone cancer	0.000258	0.00148	CcSEcCtD
Modafinil—Nervousness—Epirubicin—bone cancer	0.000256	0.00146	CcSEcCtD
Modafinil—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000256	0.00685	CbGpPWpGaD
Modafinil—Back pain—Epirubicin—bone cancer	0.000255	0.00146	CcSEcCtD
Modafinil—Angiopathy—Doxorubicin—bone cancer	0.000254	0.00145	CcSEcCtD
Modafinil—Malaise—Methotrexate—bone cancer	0.000254	0.00145	CcSEcCtD
Modafinil—Muscle spasms—Epirubicin—bone cancer	0.000253	0.00145	CcSEcCtD
Modafinil—Immune system disorder—Doxorubicin—bone cancer	0.000253	0.00145	CcSEcCtD
Modafinil—Vertigo—Methotrexate—bone cancer	0.000253	0.00145	CcSEcCtD
Modafinil—Phenoxybenzamine—CYP3A4—bone cancer	0.000253	0.0326	CrCbGaD
Modafinil—Mediastinal disorder—Doxorubicin—bone cancer	0.000253	0.00144	CcSEcCtD
Modafinil—Chills—Doxorubicin—bone cancer	0.000251	0.00144	CcSEcCtD
Modafinil—Arrhythmia—Doxorubicin—bone cancer	0.00025	0.00143	CcSEcCtD
Modafinil—Nausea—Cisplatin—bone cancer	0.000249	0.00142	CcSEcCtD
Modafinil—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000246	0.00658	CbGpPWpGaD
Modafinil—Cough—Methotrexate—bone cancer	0.000246	0.00141	CcSEcCtD
Modafinil—Mental disorder—Doxorubicin—bone cancer	0.000246	0.0014	CcSEcCtD
Modafinil—Ill-defined disorder—Epirubicin—bone cancer	0.000245	0.0014	CcSEcCtD
Modafinil—Convulsion—Methotrexate—bone cancer	0.000244	0.0014	CcSEcCtD
Modafinil—Malnutrition—Doxorubicin—bone cancer	0.000244	0.0014	CcSEcCtD
Modafinil—Anaemia—Epirubicin—bone cancer	0.000244	0.00139	CcSEcCtD
Modafinil—Agitation—Epirubicin—bone cancer	0.000242	0.00139	CcSEcCtD
Modafinil—Flatulence—Doxorubicin—bone cancer	0.00024	0.00137	CcSEcCtD
Modafinil—Myalgia—Methotrexate—bone cancer	0.00024	0.00137	CcSEcCtD
Modafinil—Chest pain—Methotrexate—bone cancer	0.00024	0.00137	CcSEcCtD
Modafinil—Arthralgia—Methotrexate—bone cancer	0.00024	0.00137	CcSEcCtD
Modafinil—Tension—Doxorubicin—bone cancer	0.000239	0.00137	CcSEcCtD
Modafinil—Dysgeusia—Doxorubicin—bone cancer	0.000239	0.00137	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000238	0.00136	CcSEcCtD
Modafinil—Malaise—Epirubicin—bone cancer	0.000238	0.00136	CcSEcCtD
Modafinil—Discomfort—Methotrexate—bone cancer	0.000237	0.00136	CcSEcCtD
Modafinil—Nervousness—Doxorubicin—bone cancer	0.000237	0.00136	CcSEcCtD
Modafinil—Vertigo—Epirubicin—bone cancer	0.000237	0.00135	CcSEcCtD
Modafinil—Syncope—Epirubicin—bone cancer	0.000236	0.00135	CcSEcCtD
Modafinil—ADRA1B—G alpha (q) signalling events—GRM1—bone cancer	0.000236	0.00633	CbGpPWpGaD
Modafinil—Back pain—Doxorubicin—bone cancer	0.000236	0.00135	CcSEcCtD
Modafinil—Muscle spasms—Doxorubicin—bone cancer	0.000235	0.00134	CcSEcCtD
Modafinil—Palpitations—Epirubicin—bone cancer	0.000233	0.00133	CcSEcCtD
Modafinil—Confusional state—Methotrexate—bone cancer	0.000232	0.00133	CcSEcCtD
Modafinil—Loss of consciousness—Epirubicin—bone cancer	0.000232	0.00133	CcSEcCtD
Modafinil—Cough—Epirubicin—bone cancer	0.00023	0.00132	CcSEcCtD
Modafinil—Anaphylactic shock—Methotrexate—bone cancer	0.00023	0.00131	CcSEcCtD
Modafinil—Convulsion—Epirubicin—bone cancer	0.000228	0.00131	CcSEcCtD
Modafinil—Infection—Methotrexate—bone cancer	0.000228	0.00131	CcSEcCtD
Modafinil—Hypertension—Epirubicin—bone cancer	0.000228	0.0013	CcSEcCtD
Modafinil—Ill-defined disorder—Doxorubicin—bone cancer	0.000226	0.00129	CcSEcCtD
Modafinil—Nervous system disorder—Methotrexate—bone cancer	0.000225	0.00129	CcSEcCtD
Modafinil—Anaemia—Doxorubicin—bone cancer	0.000225	0.00129	CcSEcCtD
Modafinil—Chest pain—Epirubicin—bone cancer	0.000224	0.00128	CcSEcCtD
Modafinil—Arthralgia—Epirubicin—bone cancer	0.000224	0.00128	CcSEcCtD
Modafinil—Myalgia—Epirubicin—bone cancer	0.000224	0.00128	CcSEcCtD
Modafinil—Agitation—Doxorubicin—bone cancer	0.000224	0.00128	CcSEcCtD
Modafinil—Anxiety—Epirubicin—bone cancer	0.000224	0.00128	CcSEcCtD
Modafinil—Skin disorder—Methotrexate—bone cancer	0.000223	0.00128	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000223	0.00127	CcSEcCtD
Modafinil—Hyperhidrosis—Methotrexate—bone cancer	0.000222	0.00127	CcSEcCtD
Modafinil—Discomfort—Epirubicin—bone cancer	0.000222	0.00127	CcSEcCtD
Modafinil—Malaise—Doxorubicin—bone cancer	0.00022	0.00126	CcSEcCtD
Modafinil—Dry mouth—Epirubicin—bone cancer	0.00022	0.00126	CcSEcCtD
Modafinil—Vertigo—Doxorubicin—bone cancer	0.000219	0.00125	CcSEcCtD
Modafinil—Anorexia—Methotrexate—bone cancer	0.000219	0.00125	CcSEcCtD
Modafinil—Syncope—Doxorubicin—bone cancer	0.000219	0.00125	CcSEcCtD
Modafinil—Confusional state—Epirubicin—bone cancer	0.000217	0.00124	CcSEcCtD
Modafinil—Palpitations—Doxorubicin—bone cancer	0.000216	0.00123	CcSEcCtD
Modafinil—Anaphylactic shock—Epirubicin—bone cancer	0.000215	0.00123	CcSEcCtD
Modafinil—Oedema—Epirubicin—bone cancer	0.000215	0.00123	CcSEcCtD
Modafinil—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000215	0.00576	CbGpPWpGaD
Modafinil—Hypotension—Methotrexate—bone cancer	0.000215	0.00123	CcSEcCtD
Modafinil—Loss of consciousness—Doxorubicin—bone cancer	0.000214	0.00123	CcSEcCtD
Modafinil—Infection—Epirubicin—bone cancer	0.000214	0.00122	CcSEcCtD
Modafinil—Cough—Doxorubicin—bone cancer	0.000213	0.00122	CcSEcCtD
Modafinil—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000212	0.00568	CbGpPWpGaD
Modafinil—Shock—Epirubicin—bone cancer	0.000212	0.00121	CcSEcCtD
Modafinil—Convulsion—Doxorubicin—bone cancer	0.000211	0.00121	CcSEcCtD
Modafinil—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000211	0.00566	CbGpPWpGaD
Modafinil—Nervous system disorder—Epirubicin—bone cancer	0.000211	0.00121	CcSEcCtD
Modafinil—Hypertension—Doxorubicin—bone cancer	0.000211	0.0012	CcSEcCtD
Modafinil—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00021	0.00563	CbGpPWpGaD
Modafinil—Tachycardia—Epirubicin—bone cancer	0.00021	0.0012	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000209	0.0012	CcSEcCtD
Modafinil—Skin disorder—Epirubicin—bone cancer	0.000209	0.0012	CcSEcCtD
Modafinil—Hyperhidrosis—Epirubicin—bone cancer	0.000208	0.00119	CcSEcCtD
Modafinil—Insomnia—Methotrexate—bone cancer	0.000208	0.00119	CcSEcCtD
Modafinil—Chest pain—Doxorubicin—bone cancer	0.000208	0.00119	CcSEcCtD
Modafinil—Arthralgia—Doxorubicin—bone cancer	0.000208	0.00119	CcSEcCtD
Modafinil—Myalgia—Doxorubicin—bone cancer	0.000208	0.00119	CcSEcCtD
Modafinil—Anxiety—Doxorubicin—bone cancer	0.000207	0.00118	CcSEcCtD
Modafinil—Paraesthesia—Methotrexate—bone cancer	0.000206	0.00118	CcSEcCtD
Modafinil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000206	0.00118	CcSEcCtD
Modafinil—Discomfort—Doxorubicin—bone cancer	0.000205	0.00117	CcSEcCtD
Modafinil—Anorexia—Epirubicin—bone cancer	0.000205	0.00117	CcSEcCtD
Modafinil—Dyspnoea—Methotrexate—bone cancer	0.000205	0.00117	CcSEcCtD
Modafinil—Methadone—CYP3A4—bone cancer	0.000205	0.0264	CrCbGaD
Modafinil—Somnolence—Methotrexate—bone cancer	0.000204	0.00117	CcSEcCtD
Modafinil—Dry mouth—Doxorubicin—bone cancer	0.000203	0.00116	CcSEcCtD
Modafinil—Dyspepsia—Methotrexate—bone cancer	0.000202	0.00116	CcSEcCtD
Modafinil—Hypotension—Epirubicin—bone cancer	0.000201	0.00115	CcSEcCtD
Modafinil—Confusional state—Doxorubicin—bone cancer	0.000201	0.00115	CcSEcCtD
Modafinil—Orphenadrine—CYP3A4—bone cancer	0.000201	0.0258	CrCbGaD
Modafinil—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0002	0.00537	CbGpPWpGaD
Modafinil—Decreased appetite—Methotrexate—bone cancer	0.0002	0.00114	CcSEcCtD
Modafinil—Oedema—Doxorubicin—bone cancer	0.000199	0.00114	CcSEcCtD
Modafinil—Anaphylactic shock—Doxorubicin—bone cancer	0.000199	0.00114	CcSEcCtD
Modafinil—Gastrointestinal disorder—Methotrexate—bone cancer	0.000199	0.00114	CcSEcCtD
Modafinil—Fatigue—Methotrexate—bone cancer	0.000198	0.00113	CcSEcCtD
Modafinil—Infection—Doxorubicin—bone cancer	0.000198	0.00113	CcSEcCtD
Modafinil—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000198	0.00529	CbGpPWpGaD
Modafinil—Pain—Methotrexate—bone cancer	0.000197	0.00112	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000196	0.00112	CcSEcCtD
Modafinil—Shock—Doxorubicin—bone cancer	0.000196	0.00112	CcSEcCtD
Modafinil—Nervous system disorder—Doxorubicin—bone cancer	0.000195	0.00112	CcSEcCtD
Modafinil—Insomnia—Epirubicin—bone cancer	0.000195	0.00111	CcSEcCtD
Modafinil—Tachycardia—Doxorubicin—bone cancer	0.000194	0.00111	CcSEcCtD
Modafinil—Skin disorder—Doxorubicin—bone cancer	0.000193	0.00111	CcSEcCtD
Modafinil—Paraesthesia—Epirubicin—bone cancer	0.000193	0.00111	CcSEcCtD
Modafinil—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000193	0.00517	CbGpPWpGaD
Modafinil—Hyperhidrosis—Doxorubicin—bone cancer	0.000192	0.0011	CcSEcCtD
Modafinil—Dyspnoea—Epirubicin—bone cancer	0.000192	0.0011	CcSEcCtD
Modafinil—Somnolence—Epirubicin—bone cancer	0.000191	0.00109	CcSEcCtD
Modafinil—Anorexia—Doxorubicin—bone cancer	0.00019	0.00109	CcSEcCtD
Modafinil—Feeling abnormal—Methotrexate—bone cancer	0.000189	0.00108	CcSEcCtD
Modafinil—Dyspepsia—Epirubicin—bone cancer	0.000189	0.00108	CcSEcCtD
Modafinil—Gastrointestinal pain—Methotrexate—bone cancer	0.000188	0.00108	CcSEcCtD
Modafinil—Decreased appetite—Epirubicin—bone cancer	0.000187	0.00107	CcSEcCtD
Modafinil—Hypotension—Doxorubicin—bone cancer	0.000186	0.00106	CcSEcCtD
Modafinil—Gastrointestinal disorder—Epirubicin—bone cancer	0.000186	0.00106	CcSEcCtD
Modafinil—Fatigue—Epirubicin—bone cancer	0.000186	0.00106	CcSEcCtD
Modafinil—Pain—Epirubicin—bone cancer	0.000184	0.00105	CcSEcCtD
Modafinil—Constipation—Epirubicin—bone cancer	0.000184	0.00105	CcSEcCtD
Modafinil—Urticaria—Methotrexate—bone cancer	0.000183	0.00104	CcSEcCtD
Modafinil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000183	0.00489	CbGpPWpGaD
Modafinil—ADRA1B—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000183	0.00489	CbGpPWpGaD
Modafinil—Abdominal pain—Methotrexate—bone cancer	0.000182	0.00104	CcSEcCtD
Modafinil—Body temperature increased—Methotrexate—bone cancer	0.000182	0.00104	CcSEcCtD
Modafinil—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000181	0.00104	CcSEcCtD
Modafinil—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00018	0.00483	CbGpPWpGaD
Modafinil—Insomnia—Doxorubicin—bone cancer	0.00018	0.00103	CcSEcCtD
Modafinil—Paraesthesia—Doxorubicin—bone cancer	0.000179	0.00102	CcSEcCtD
Modafinil—Dyspnoea—Doxorubicin—bone cancer	0.000178	0.00102	CcSEcCtD
Modafinil—Feeling abnormal—Epirubicin—bone cancer	0.000177	0.00101	CcSEcCtD
Modafinil—Somnolence—Doxorubicin—bone cancer	0.000177	0.00101	CcSEcCtD
Modafinil—Gastrointestinal pain—Epirubicin—bone cancer	0.000176	0.00101	CcSEcCtD
Modafinil—Dyspepsia—Doxorubicin—bone cancer	0.000175	0.001	CcSEcCtD
Modafinil—Decreased appetite—Doxorubicin—bone cancer	0.000173	0.00099	CcSEcCtD
Modafinil—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000172	0.000983	CcSEcCtD
Modafinil—Fatigue—Doxorubicin—bone cancer	0.000172	0.000982	CcSEcCtD
Modafinil—Urticaria—Epirubicin—bone cancer	0.000171	0.000978	CcSEcCtD
Modafinil—Constipation—Doxorubicin—bone cancer	0.00017	0.000974	CcSEcCtD
Modafinil—Pain—Doxorubicin—bone cancer	0.00017	0.000974	CcSEcCtD
Modafinil—Abdominal pain—Epirubicin—bone cancer	0.00017	0.000973	CcSEcCtD
Modafinil—Body temperature increased—Epirubicin—bone cancer	0.00017	0.000973	CcSEcCtD
Modafinil—Hypersensitivity—Methotrexate—bone cancer	0.000169	0.000969	CcSEcCtD
Modafinil—ADRA1B—LPA receptor mediated events—MMP2—bone cancer	0.000168	0.00451	CbGpPWpGaD
Modafinil—SLC6A3—NRF2 pathway—GSTP1—bone cancer	0.000165	0.00442	CbGpPWpGaD
Modafinil—SLC6A3—NRF2 pathway—TGFBR2—bone cancer	0.000165	0.00442	CbGpPWpGaD
Modafinil—Asthenia—Methotrexate—bone cancer	0.000165	0.000943	CcSEcCtD
Modafinil—Feeling abnormal—Doxorubicin—bone cancer	0.000164	0.000938	CcSEcCtD
Modafinil—Gastrointestinal pain—Doxorubicin—bone cancer	0.000163	0.000931	CcSEcCtD
Modafinil—Pruritus—Methotrexate—bone cancer	0.000163	0.00093	CcSEcCtD
Modafinil—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000162	0.00435	CbGpPWpGaD
Modafinil—Hypersensitivity—Epirubicin—bone cancer	0.000159	0.000907	CcSEcCtD
Modafinil—Urticaria—Doxorubicin—bone cancer	0.000158	0.000905	CcSEcCtD
Modafinil—Body temperature increased—Doxorubicin—bone cancer	0.000157	0.0009	CcSEcCtD
Modafinil—Abdominal pain—Doxorubicin—bone cancer	0.000157	0.0009	CcSEcCtD
Modafinil—Diarrhoea—Methotrexate—bone cancer	0.000157	0.0009	CcSEcCtD
Modafinil—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000156	0.00418	CbGpPWpGaD
Modafinil—Asthenia—Epirubicin—bone cancer	0.000154	0.000883	CcSEcCtD
Modafinil—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000154	0.00413	CbGpPWpGaD
Modafinil—Pruritus—Epirubicin—bone cancer	0.000152	0.000871	CcSEcCtD
Modafinil—ADRA1B—G alpha (q) signalling events—GNA11—bone cancer	0.000152	0.00408	CbGpPWpGaD
Modafinil—Dizziness—Methotrexate—bone cancer	0.000152	0.00087	CcSEcCtD
Modafinil—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000148	0.00397	CbGpPWpGaD
Modafinil—Diarrhoea—Epirubicin—bone cancer	0.000147	0.000842	CcSEcCtD
Modafinil—Hypersensitivity—Doxorubicin—bone cancer	0.000147	0.000839	CcSEcCtD
Modafinil—Vomiting—Methotrexate—bone cancer	0.000146	0.000836	CcSEcCtD
Modafinil—Rash—Methotrexate—bone cancer	0.000145	0.000829	CcSEcCtD
Modafinil—Dermatitis—Methotrexate—bone cancer	0.000145	0.000828	CcSEcCtD
Modafinil—Headache—Methotrexate—bone cancer	0.000144	0.000824	CcSEcCtD
Modafinil—Asthenia—Doxorubicin—bone cancer	0.000143	0.000817	CcSEcCtD
Modafinil—Dizziness—Epirubicin—bone cancer	0.000142	0.000814	CcSEcCtD
Modafinil—Pruritus—Doxorubicin—bone cancer	0.000141	0.000806	CcSEcCtD
Modafinil—ADRA1B—GPCR ligand binding—GRM4—bone cancer	0.000137	0.00368	CbGpPWpGaD
Modafinil—Vomiting—Epirubicin—bone cancer	0.000137	0.000782	CcSEcCtD
Modafinil—Nausea—Methotrexate—bone cancer	0.000137	0.000781	CcSEcCtD
Modafinil—Diarrhoea—Doxorubicin—bone cancer	0.000136	0.000779	CcSEcCtD
Modafinil—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000136	0.00365	CbGpPWpGaD
Modafinil—Rash—Epirubicin—bone cancer	0.000136	0.000776	CcSEcCtD
Modafinil—Dermatitis—Epirubicin—bone cancer	0.000136	0.000775	CcSEcCtD
Modafinil—Headache—Epirubicin—bone cancer	0.000135	0.000771	CcSEcCtD
Modafinil—Dizziness—Doxorubicin—bone cancer	0.000132	0.000753	CcSEcCtD
Modafinil—ADRA1B—LPA receptor mediated events—JUN—bone cancer	0.00013	0.00348	CbGpPWpGaD
Modafinil—SLC6A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00013	0.00348	CbGpPWpGaD
Modafinil—Nausea—Epirubicin—bone cancer	0.000128	0.000731	CcSEcCtD
Modafinil—Vomiting—Doxorubicin—bone cancer	0.000127	0.000724	CcSEcCtD
Modafinil—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000127	0.00339	CbGpPWpGaD
Modafinil—ADRA1B—LPA receptor mediated events—MMP9—bone cancer	0.000126	0.00339	CbGpPWpGaD
Modafinil—Rash—Doxorubicin—bone cancer	0.000126	0.000718	CcSEcCtD
Modafinil—Dermatitis—Doxorubicin—bone cancer	0.000125	0.000717	CcSEcCtD
Modafinil—Headache—Doxorubicin—bone cancer	0.000125	0.000713	CcSEcCtD
Modafinil—ADRA1B—GPCR ligand binding—GRM1—bone cancer	0.000119	0.00319	CbGpPWpGaD
Modafinil—Nausea—Doxorubicin—bone cancer	0.000118	0.000676	CcSEcCtD
Modafinil—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000114	0.00306	CbGpPWpGaD
Modafinil—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000113	0.00302	CbGpPWpGaD
Modafinil—SLC6A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000112	0.003	CbGpPWpGaD
Modafinil—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000112	0.00299	CbGpPWpGaD
Modafinil—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.00011	0.00295	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000104	0.00279	CbGpPWpGaD
Modafinil—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000103	0.00275	CbGpPWpGaD
Modafinil—ADRA1B—LPA receptor mediated events—EGFR—bone cancer	0.000102	0.00274	CbGpPWpGaD
Modafinil—CYP1A2—Phase II conjugation—GSTP1—bone cancer	9.83e-05	0.00263	CbGpPWpGaD
Modafinil—CYP2B6—Biological oxidations—GSTP1—bone cancer	9.76e-05	0.00261	CbGpPWpGaD
Modafinil—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	9.63e-05	0.00258	CbGpPWpGaD
Modafinil—CYP3A5—Biological oxidations—GSTP1—bone cancer	9.54e-05	0.00256	CbGpPWpGaD
Modafinil—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	9.41e-05	0.00252	CbGpPWpGaD
Modafinil—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	9.36e-05	0.00251	CbGpPWpGaD
Modafinil—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	8.87e-05	0.00238	CbGpPWpGaD
Modafinil—CYP2C19—Biological oxidations—CYP3A4—bone cancer	8.63e-05	0.00231	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	8.55e-05	0.00229	CbGpPWpGaD
Modafinil—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	8.51e-05	0.00228	CbGpPWpGaD
Modafinil—ADRA1B—GPCR ligand binding—SMO—bone cancer	8.39e-05	0.00225	CbGpPWpGaD
Modafinil—SLC6A3—Transmission across Chemical Synapses—BRAF—bone cancer	8.24e-05	0.00221	CbGpPWpGaD
Modafinil—ADRA1B—AMPK Signaling—TP53—bone cancer	8.08e-05	0.00216	CbGpPWpGaD
Modafinil—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	8e-05	0.00214	CbGpPWpGaD
Modafinil—CYP2C9—Biological oxidations—CYP3A4—bone cancer	7.87e-05	0.00211	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—GRM4—bone cancer	7.76e-05	0.00208	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—RGS1—bone cancer	7.76e-05	0.00208	CbGpPWpGaD
Modafinil—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.76e-05	0.00208	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.71e-05	0.00207	CbGpPWpGaD
Modafinil—CYP2C19—Biological oxidations—GSTP1—bone cancer	7.38e-05	0.00198	CbGpPWpGaD
Modafinil—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	7.28e-05	0.00195	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—RGS1—bone cancer	7.05e-05	0.00189	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—GRM4—bone cancer	7.05e-05	0.00189	CbGpPWpGaD
Modafinil—SLC6A3—Transmission across Chemical Synapses—MDM2—bone cancer	6.9e-05	0.00185	CbGpPWpGaD
Modafinil—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.85e-05	0.00183	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—NDUFA12—bone cancer	6.84e-05	0.00183	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—GRM1—bone cancer	6.73e-05	0.0018	CbGpPWpGaD
Modafinil—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.73e-05	0.0018	CbGpPWpGaD
Modafinil—CYP1A2—Biological oxidations—CYP3A4—bone cancer	6.72e-05	0.0018	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—NDUFA12—bone cancer	6.69e-05	0.00179	CbGpPWpGaD
Modafinil—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.63e-05	0.00178	CbGpPWpGaD
Modafinil—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	6.63e-05	0.00178	CbGpPWpGaD
Modafinil—SLC6A3—Neuronal System—BRAF—bone cancer	6.31e-05	0.00169	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—GRM1—bone cancer	6.11e-05	0.00164	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.06e-05	0.00162	CbGpPWpGaD
Modafinil—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.06e-05	0.00162	CbGpPWpGaD
Modafinil—CYP1A2—Biological oxidations—GSTP1—bone cancer	5.75e-05	0.00154	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—NT5C3A—bone cancer	5.67e-05	0.00152	CbGpPWpGaD
Modafinil—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	5.67e-05	0.00152	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—NT5C3A—bone cancer	5.54e-05	0.00148	CbGpPWpGaD
Modafinil—SLC6A3—Neuronal System—MDM2—bone cancer	5.29e-05	0.00142	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NDUFA12—bone cancer	5.17e-05	0.00138	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NDUFA12—bone cancer	4.71e-05	0.00126	CbGpPWpGaD
Modafinil—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.44e-05	0.00119	CbGpPWpGaD
Modafinil—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.38e-05	0.00117	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—GNA11—bone cancer	4.34e-05	0.00116	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—SMO—bone cancer	4.31e-05	0.00115	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—NT5C3A—bone cancer	4.28e-05	0.00115	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—GRM4—bone cancer	4.16e-05	0.00112	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—RGS1—bone cancer	4.16e-05	0.00112	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NDUFA12—bone cancer	4.03e-05	0.00108	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—GNA11—bone cancer	3.94e-05	0.00105	CbGpPWpGaD
Modafinil—ADRA1B—GPCR downstream signaling—IL3—bone cancer	3.93e-05	0.00105	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—NT5C3A—bone cancer	3.91e-05	0.00105	CbGpPWpGaD
Modafinil—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.88e-05	0.00104	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—GRM1—bone cancer	3.61e-05	0.000967	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—IL3—bone cancer	3.57e-05	0.000956	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—NT5C3A—bone cancer	3.34e-05	0.000894	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NDUFA12—bone cancer	3.11e-05	0.000833	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—NT5C3A—bone cancer	2.58e-05	0.00069	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—SMO—bone cancer	2.54e-05	0.000681	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—ENO2—bone cancer	2.48e-05	0.000665	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—ENO2—bone cancer	2.43e-05	0.00065	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—GNA11—bone cancer	2.33e-05	0.000623	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—DHFR—bone cancer	2.3e-05	0.000617	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—DHFR—bone cancer	2.25e-05	0.000603	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—ATF1—bone cancer	2.16e-05	0.000579	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GNA11—bone cancer	2.15e-05	0.000577	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IL3—bone cancer	2.11e-05	0.000565	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GNA11—bone cancer	2.1e-05	0.000564	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—CYP3A4—bone cancer	1.95e-05	0.000523	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—CYP3A4—bone cancer	1.91e-05	0.000511	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—ENO2—bone cancer	1.88e-05	0.000503	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TGFBR2—bone cancer	1.8e-05	0.000483	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—DHFR—bone cancer	1.74e-05	0.000466	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—ENO2—bone cancer	1.71e-05	0.000458	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—IGF1R—bone cancer	1.7e-05	0.000455	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—GSTP1—bone cancer	1.67e-05	0.000447	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—GSTP1—bone cancer	1.63e-05	0.000437	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GNA11—bone cancer	1.63e-05	0.000436	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—DHFR—bone cancer	1.59e-05	0.000425	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GNA11—bone cancer	1.48e-05	0.000397	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—CYP3A4—bone cancer	1.48e-05	0.000395	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.47e-05	0.000393	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—ENO2—bone cancer	1.46e-05	0.000392	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—DHFR—bone cancer	1.36e-05	0.000363	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—CYP3A4—bone cancer	1.35e-05	0.00036	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.34e-05	0.000358	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GNA11—bone cancer	1.27e-05	0.00034	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—GSTP1—bone cancer	1.26e-05	0.000338	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—KIT—bone cancer	1.23e-05	0.00033	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—BRAF—bone cancer	1.16e-05	0.00031	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—GSTP1—bone cancer	1.15e-05	0.000308	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—CYP3A4—bone cancer	1.15e-05	0.000308	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.14e-05	0.000306	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—ENO2—bone cancer	1.13e-05	0.000302	CbGpPWpGaD
Modafinil—ADRA1B—Signaling by GPCR—EGFR—bone cancer	1.12e-05	0.0003	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—DHFR—bone cancer	1.05e-05	0.00028	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—GSTP1—bone cancer	9.83e-06	0.000263	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GNA11—bone cancer	9.78e-06	0.000262	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MDM2—bone cancer	9.7e-06	0.00026	CbGpPWpGaD
Modafinil—CYP2B6—Metabolism—PTGS2—bone cancer	8.65e-06	0.000232	CbGpPWpGaD
Modafinil—CYP3A5—Metabolism—PTGS2—bone cancer	8.45e-06	0.000226	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—JUN—bone cancer	8.43e-06	0.000226	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—MMP9—bone cancer	8.2e-06	0.00022	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—GSTP1—bone cancer	7.59e-06	0.000203	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—EGFR—bone cancer	6.63e-06	0.000177	CbGpPWpGaD
Modafinil—CYP2C19—Metabolism—PTGS2—bone cancer	6.54e-06	0.000175	CbGpPWpGaD
Modafinil—CYP2C9—Metabolism—PTGS2—bone cancer	5.96e-06	0.00016	CbGpPWpGaD
Modafinil—ADRA1B—Signaling Pathways—TP53—bone cancer	5.56e-06	0.000149	CbGpPWpGaD
Modafinil—CYP1A2—Metabolism—PTGS2—bone cancer	5.09e-06	0.000136	CbGpPWpGaD
Modafinil—CYP3A4—Metabolism—PTGS2—bone cancer	3.93e-06	0.000105	CbGpPWpGaD
